Radiopharm Theranostics Ltd (RAD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Radiopharm Theranostics Ltd (RAD) has a cash flow conversion efficiency ratio of -0.337x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-14.43 Million ≈ $-10.21 Million USD) by net assets (AU$42.87 Million ≈ $30.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Radiopharm Theranostics Ltd - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Radiopharm Theranostics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read RAD liabilities breakdown for a breakdown of total debt and financial obligations.
Radiopharm Theranostics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Radiopharm Theranostics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jeongsan Aikang Co.Ltd
KQ:022220
|
0.002x |
|
Gold Strike Resources Corp.
V:GSR
|
-2.876x |
|
Duc Long Gia Lai Group JSC
VN:DLG
|
-0.523x |
|
Sentronic International
TWO:3232
|
0.055x |
|
KB Autosys Co. Ltd
KQ:024120
|
-0.009x |
|
KH Group Oyj
HE:KHG
|
0.568x |
|
Seafire AB
ST:SEAF
|
-0.015x |
|
Daeho Al Co. Ltd.
KO:069460
|
0.081x |
Annual Cash Flow Conversion Efficiency for Radiopharm Theranostics Ltd (2021–2025)
The table below shows the annual cash flow conversion efficiency of Radiopharm Theranostics Ltd from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Radiopharm Theranostics Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$42.87 Million ≈ $30.33 Million |
AU$-36.65 Million ≈ $-25.93 Million |
-0.855x | -1.76% |
| 2024-06-30 | AU$27.35 Million ≈ $19.35 Million |
AU$-22.98 Million ≈ $-16.26 Million |
-0.840x | -65.01% |
| 2023-06-30 | AU$45.58 Million ≈ $32.25 Million |
AU$-23.20 Million ≈ $-16.42 Million |
-0.509x | -223.52% |
| 2022-06-30 | AU$62.96 Million ≈ $44.55 Million |
AU$-9.91 Million ≈ $-7.01 Million |
-0.157x | -159.62% |
| 2021-06-30 | AU$-124.70K ≈ $-88.24K |
AU$-32.91K ≈ $-23.29K |
0.264x | -- |
About Radiopharm Theranostics Ltd
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more